Ge Zhaorui, Li Chunyan, Liu Yanling, Sun Xiujuan
Department of Internal Medicine, Xianxian Hospital of Traditional Chinese Medicine, Xianxian, 062250, People's Republic of China.
Department of Cardiology, The Second Affiliated Hospital of Hebei North University, Baoding, People's Republic of China.
Int J Gen Med. 2025 Apr 7;18:1999-2008. doi: 10.2147/IJGM.S509162. eCollection 2025.
To analyze the effect of recombinant human brain natriuretic peptide (rhBNP) combined with Xinmailong on heart failure and its impact on cardiac function and inflammatory response.
A retrospective analysis was conducted on the clinical data of 60 heart failure patients treated in our hospital from January 2023 to March 2024. The patients were included as research subjects to ensure the sample was representative. According to the different treatment methods, the patients were divided into two groups: the control group received only rhBNP treatment, and the experimental group received combined treatment with rhBNP and Xinmailong injection, with 30 patients in each group. The clinical effects, cardiac function, inflammatory response, and ventricular remodeling indicators of the two groups before and after treatment were observed and compared.
The total clinical effective rate of the experimental group was significantly higher than that of the control group (P<0.05). After treatment, the NT-proBNP level in the experimental group was significantly lower than that in the control group (P<0.05). After treatment, the levels of IL-6, TNF-α, and CRP in the experimental group were significantly lower than those in the control group (P<0.05). After treatment, the LVESD and LVEDD levels in the experimental group were significantly lower than those in the control group, while the LVEF level was higher in the experimental group than in the control group (P<0.05). There was no significant difference in the adverse event incidence between the two groups (P>0.05). The 6-minute walk test (6 MWT) level in the experimental group was significantly higher than in the control group (P<0.05).
Recombinant human brain natriuretic peptide combined with Xinmailong is effective in treating heart failure, significantly improving cardiac function, reducing inflammatory responses, and reversing ventricular remodeling. It is also safe and beneficial for the patients' prognosis.
分析重组人脑利钠肽（rhBNP）联合心脉隆对心力衰竭的影响及其对心功能和炎症反应的作用。
回顾性分析2023年1月至2024年3月在我院治疗的60例心力衰竭患者的临床资料。将患者纳入研究对象以确保样本具有代表性。根据不同治疗方法，将患者分为两组：对照组仅接受rhBNP治疗，试验组接受rhBNP与心脉隆注射液联合治疗，每组30例。观察并比较两组治疗前后的临床疗效、心功能、炎症反应及心室重构指标。
试验组总临床有效率显著高于对照组（P<0.05）。治疗后，试验组NT-proBNP水平显著低于对照组（P<0.05）。治疗后，试验组IL-6、TNF-α和CRP水平显著低于对照组（P<0.05）。治疗后，试验组LVESD和LVEDD水平显著低于对照组，而试验组LVEF水平高于对照组（P<0.05）。两组不良事件发生率无显著差异（P>0.05）。试验组6分钟步行试验（6MWT）水平显著高于对照组（P<0.05）。
重组人脑利钠肽联合心脉隆治疗心力衰竭有效，可显著改善心功能，减轻炎症反应，逆转心室重构。对患者预后也安全有益。
